Last updated: February 14, 2026
What Is the Current Market Position of NDC 53746-0670?
NDC 53746-0670 is a medication listed in the national drug code database. It is identified as Vyvgart (efgartigimod-alpha-fcy), marketed by Argenx. Approved by the FDA in June 2021 for generalized myasthenia gravis (gMG), it targets the neonatal Fc receptor (FcRn), helping reduce pathogenic IgG antibodies in autoimmune conditions.
How Large is the Market for Vyvgart?
The primary indication—generalized myasthenia gravis—has an estimated patient population of 20,000 to 30,000 cases in the U.S., according to the Myasthenia Gravis Foundation. The drug's role as a targeted therapy positions it as a significant new treatment option, particularly for refractory patients.
Competitor Landscape
- Eculizumab (Soliris): Estimated at $6 billion in annual sales globally; approved since 2007 for gMG among other indications.
- RimabotulinumtoxinB (Myobloc) and other immunosuppressants have lesser share in gMG but are used off-label or for different autoimmune conditions.
Market Share and Penetration
The efficacy of Vyvgart in treatment-resistant patients and its safety profile will influence its market share. Market adoption projections vary:
| Scenario |
Year 1 |
Year 3 |
Year 5 |
| Conservative (10% of treated patients) |
$150M |
$400M |
$800M |
| Moderate (25%) |
$375M |
$1.0B |
$2.0B |
| Aggressive (50%) |
$750M |
$2.0B |
$4.0B |
Based on clinical trial data, annual revenue could range between $150 million and $4 billion over five years, depending on uptake, pricing, and competitive pressures.
What Are the Pricing Trends for Vyvgart?
Vyvgart's list price is approximately $17,000 per infusion, with dosing based on weight and administered every 2 weeks. This results in:
| Pricing Metric |
Value |
| Per-dose price |
$17,000 |
| Typical annual doses |
26 infusions (~1 every two weeks) |
| Estimated annual cost |
$442,000 (assuming full dosing) |
Adjustments are common for real-world practice, including dose reductions with certain protocols or insurance negotiations.
Price Benchmarks
- Compared to Soliris ($6,000+ per infusion), Vyvgart's pricing is within the high-end of biologics but benefits from potentially reduced infusion frequency in some protocols.
- Reimbursement and formulary inclusion are likely to influence the actual price paid by payers.
What Are the Key Drivers for Market and Price Projection?
Regulatory Factors:
- US/EU approvals: Vyvgart has FDA approval; EMA approval pending. Expanded approvals for other autoimmune conditions may boost sales.
- Off-label use: Potential expansion into other IgG-mediated autoimmune diseases increases growth opportunities.
Clinical Data:
- Efficacy and safety from the ADAPT study support its positioning. Head-to-head data with existing treatments could influence market share.
Reimbursement policies:
- Payer coverage decides access; negotiation of discounts and formulary placement impact net revenue.
Commercial Strategies:
- Launch tactics, pricing negotiations, and indication expansion will shape market penetration.
How Will Pricing Evolve Over the Next Five Years?
- Initial pricing remains stable, with possible discounts ranging from 10% to 30% for large payers or specialty pharmacy arrangements.
- Medicaid and Medicare negotiations may pressure net prices downward.
- Competition from biosimilars or alternative therapies could result in price erosion, especially after patent expiry.
What Are the Patent and Exclusivity Factors?
- Patent protection for Vyvgart extends into the late 2030s.
- Data exclusivity may provide additional market protection until at least 2031.
- Patent challenges or biosimilar development could influence long-term pricing strategies.
Summary of Financial Outlook
| Year |
Revenue Expectation |
Notes |
| 2023 |
$150M–$300M |
Launch year, initial uptake |
| 2024 |
$300M–$600M |
Increased market penetration |
| 2025 |
$400M–$1.2B |
Expansion into additional indications |
| 2026+ |
Up to $4B |
Potential market saturation, competition impacts |
Key Takeaways
- Vyvgart targets a niche autoimmune market with emerging demand.
- Pricing remains high but subject to discounts and negotiations.
- Revenue projections depend heavily on market adoption, competition, and regulatory developments.
- Pricing strategy will adapt based on payer negotiations and competitive pressures.
- Long-term market dominance depends on patent protection and indication expansion.
FAQs
Q1: How does Vyvgart's pricing compare to other biologics for autoimmune diseases?
Vyvgart’s $17,000 per infusion aligns with high-end biologics like Soliris but remains significantly higher than smaller molecule therapies, justified by its targeted mechanism and treatment efficacy.
Q2: What factors could accelerate Vyvgart's market growth?
Expanded approval for additional autoimmune conditions, real-world effectiveness demonstrations, and successful reimbursement negotiations could increase its market share.
Q3: What could limit Vyvgart’s price and market share?
Market entry of biosimilars, costly reimbursement negotiations, and limited indication expansion potential could suppress sales and pricing.
Q4: Are there upcoming patent expiries that threaten Vyvgart's revenues?
Patent protection extends into the late 2030s, providing a period of market exclusivity barring patent challenges or biosimilar entry.
Q5: How might reimbursement policies impact Vyvgart sales?
Stringent rebate demands and formulary constraints could lower net prices and slow uptake, particularly in Medicaid and Medicare segments.
References
- [1] FDA. Vyvgart (efgartigimod-alpha-fcy) approval facts. 2021.
- [2] Myasthenia Gravis Foundation. Prevalence data. 2022.
- [3] IQVIA. Biologics pricing and sales data. 2023.
- [4] Argenx. Vyvgart prescribing information. 2021.
- [5] MarketResearch.com. Autoimmune biologics market forecast. 2022.
